Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Interestingly, Hridayapoorvam is clashing at the box office with Naslen‘s Lokah Chapter 1: Chandra. The film is supposed to have a cameo by Mohanlal as well. However, Hridayapoorvam registered 135% ...

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...

Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration (FDA) for izalontamab brengitecan (iza-bren) to treat locally advanced or ...

After an unusual first quarter in which seven of the biopharma industry’s top 25 companies—all from the U.S.—saw year-over-year revenue declines, the second quarter brought a return to normalcy as ...

After more than two decades working at the Cleveland Clinic, Nathan Pennell, M.D., Ph.D., is joining the Big Pharma fold to head up Bristol Myers Squibb’s hematology and oncology medical affairs unit ...

Founded by former OpenAI staff members and funded by Amazon and Google, Anthropic has raised the stakes in the GPT wars. Anthropic's Claude Desktop app often outshines its ChatGPT rival in various ...

Three lots of raw frozen shrimp products processed by PT. Bahari Makmur Sejati, which does business as BMS Foods, should be thrown away by consumers after some of the company's products tested ...

On Tuesday, the Food and Drug Administration (FDA) warned consumers about potential contamination of a well-known brand of frozen shrimp sold at Walmart. In a press release, the FDA urged the public ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. Xoma is set to acquire Mural for $2.035 per share, for a total value of about ...

Catalent is laying off 350 employees in its gene therapy manufacturing division in Baltimore “due to an unexpected shift in demand from a large customer, which made it necessary to reduce our ...